开云app官网登录入口网页版-官方正版

#阿那曲唑#

17篇内容 | 1225人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2194840, encodeId=57502194840ce, content=<a href='/topic/show?id=4cce112601bc' target=_blank style='color:#2F92EE;'>#Giredestrant#</a> <a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a> <a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, objectTitle=Lancet Oncol | coopERA Breast Cancer研究：新辅助哌柏西利加giredestrant或阿那曲唑治疗雌激素受体阳性、HER2阴性的乳腺癌, objectType=article, longId=817767, objectId=605081e76707, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240322/1711117195034_6145188.jpg, objectUrl=/article/show_article.do?id=605081e76707, replyNumber=0, likeNumber=110, createdTime=2024-03-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=605081e76707, moduleTitle=Lancet Oncol | coopERA Breast Cancer研究：新辅助哌柏西利加giredestrant或阿那曲唑治疗雌激素受体阳性、HER2阴性的乳腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=605081e76707)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1412273, encodeId=5b3c14122e389, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=JAMA Oncol：Vistusertib联合阿那曲唑治疗激素受体阳性子宫内膜癌, objectType=article, longId=727038, objectId=8cb4e270380d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8cb4e270380d, replyNumber=0, likeNumber=64, createdTime=2022-05-17, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cb4e270380d, moduleTitle=JAMA Oncol：Vistusertib联合阿那曲唑治疗激素受体阳性子宫内膜癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8cb4e270380d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412272, encodeId=98b914122e2ff, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=Brit J Cancer：接受阿那曲唑治疗5年的绝经后妇女骨密度变化, objectType=article, longId=206251, objectId=bbfe206251e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbfe206251e6, replyNumber=0, likeNumber=67, createdTime=2021-01-27, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbfe206251e6, moduleTitle=Brit J Cancer：接受阿那曲唑治疗5年的绝经后妇女骨密度变化, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bbfe206251e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412271, encodeId=60f114122e1a8, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=Lancet：阿那曲唑用于乳腺癌的预防, objectType=article, longId=184854, objectId=745318485430, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=745318485430, replyNumber=0, likeNumber=75, createdTime=2019-12-18, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=745318485430, moduleTitle=Lancet：阿那曲唑用于乳腺癌的预防, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=745318485430)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412270, encodeId=7b6f14122e015, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=CLIN CANCER RES：AKT抑制剂MK-2206联合阿那曲唑治疗Ⅱ/Ⅲ期PIK3CA突变ER阳性和HER-2阴性乳腺癌, objectType=article, longId=120634, objectId=1dba1206345c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1dba1206345c, replyNumber=0, likeNumber=54, createdTime=2017-11-20, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dba1206345c, moduleTitle=CLIN CANCER RES：AKT抑制剂MK-2206联合阿那曲唑治疗Ⅱ/Ⅲ期PIK3CA突变ER阳性和HER-2阴性乳腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1dba1206345c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412269, encodeId=58691412269aa, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=JNCI：化疗引发卵巢功能衰竭的乳腺癌患者使用阿那曲唑有无获益？, objectType=article, longId=118687, objectId=96f711868ef5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96f711868ef5, replyNumber=0, likeNumber=70, createdTime=2017-11-05, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96f711868ef5, moduleTitle=JNCI：化疗引发卵巢功能衰竭的乳腺癌患者使用阿那曲唑有无获益？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=96f711868ef5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412268, encodeId=eada1412268d8, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验, objectType=article, longId=103156, objectId=d8d010315642, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8d010315642, replyNumber=0, likeNumber=45, createdTime=2017-06-25, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8d010315642, moduleTitle=Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d8d010315642)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412267, encodeId=8ed9141226e85, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=Fertil Steril：雄激素缺乏生育力低下男性接受阿那曲唑结局有何改善？, objectType=article, longId=95899, objectId=dcef9589920, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcef9589920, replyNumber=0, likeNumber=68, createdTime=2017-04-16, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcef9589920, moduleTitle=Fertil Steril：雄激素缺乏生育力低下男性接受阿那曲唑结局有何改善？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dcef9589920)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412266, encodeId=512d14122660f, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=Fertil Steril.：雄激素缺乏生育力低下男性接受阿那曲唑结局有何改善？, objectType=article, longId=95897, objectId=43239589ea8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43239589ea8, replyNumber=0, likeNumber=67, createdTime=2017-04-16, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43239589ea8, moduleTitle=Fertil Steril.：雄激素缺乏生育力低下男性接受阿那曲唑结局有何改善？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=43239589ea8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412265, encodeId=043d141226553, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=Lancet：对于雌激素受体阳性的晚期乳腺癌患者氟维司群疗效比阿那曲唑更好, objectType=article, longId=83273, objectId=a635832e3b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a635832e3b6, replyNumber=0, likeNumber=61, createdTime=2016-12-01, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a635832e3b6, moduleTitle=Lancet：对于雌激素受体阳性的晚期乳腺癌患者氟维司群疗效比阿那曲唑更好, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a635832e3b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412264, encodeId=f7b0141226468, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=阿斯利康抗癌药Faslodex（氟维司群）治疗HR+晚期乳腺癌疗效显著优于Arimidex（阿那曲唑）, objectType=article, longId=69402, objectId=83826940262, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83826940262, replyNumber=0, likeNumber=64, createdTime=2016-05-30, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83826940262, moduleTitle=阿斯利康抗癌药Faslodex（氟维司群）治疗HR+晚期乳腺癌疗效显著优于Arimidex（阿那曲唑）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=83826940262)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412263, encodeId=184914122635f, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=Lancet：阿那曲唑 vs 他莫昔芬治疗对导管原位癌切除的绝经后女性生活质量的影响, objectType=article, longId=60509, objectId=3b6360509bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b6360509bd, replyNumber=0, likeNumber=67, createdTime=2015-12-12, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b6360509bd, moduleTitle=Lancet：阿那曲唑 vs 他莫昔芬治疗对导管原位癌切除的绝经后女性生活质量的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3b6360509bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412262, encodeId=10da141226258, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=Lancet ：阿那曲唑治疗绝经后女性乳腺导管癌患者效果优于他莫昔芬, objectType=article, longId=60508, objectId=b22160508c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b22160508c7, replyNumber=0, likeNumber=67, createdTime=2015-12-12, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b22160508c7, moduleTitle=Lancet ：阿那曲唑治疗绝经后女性乳腺导管癌患者效果优于他莫昔芬, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b22160508c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412261, encodeId=584b1412261fe, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=JCO：阿那曲唑与腕管综合征发病率增高有关（基于国际乳腺癌干预研究II）, objectType=article, longId=59405, objectId=9792594051e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9792594051e, replyNumber=0, likeNumber=59, createdTime=2015-11-26, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9792594051e, moduleTitle=JCO：阿那曲唑与腕管综合征发病率增高有关（基于国际乳腺癌干预研究II）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9792594051e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412260, encodeId=f3b1141226011, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=Lancet Oncology：IBIS-II试验利塞膦酸钠可提高阿那曲唑骨质流失风险效益比, objectType=article, longId=42479, objectId=192c424e930, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=192c424e930, replyNumber=0, likeNumber=68, createdTime=2014-11-13, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=192c424e930, moduleTitle=Lancet Oncology：IBIS-II试验利塞膦酸钠可提高阿那曲唑骨质流失风险效益比, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=192c424e930)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412259, encodeId=9e6e1412259e2, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=Lancet：阿那曲唑，乳腺癌预防新选择, objectType=article, longId=28579, objectId=f524285e9b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f524285e9b1, replyNumber=0, likeNumber=62, createdTime=2013-12-27, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f524285e9b1, moduleTitle=Lancet：阿那曲唑，乳腺癌预防新选择, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f524285e9b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412258, encodeId=3cee141225891, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=NEJM：阿那曲唑+氟维司群联合用药可延长乳腺癌患者生存, objectType=article, longId=8550, objectId=f2f085501d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2f085501d, replyNumber=0, likeNumber=63, createdTime=2012-08-05, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2f085501d, moduleTitle=NEJM：阿那曲唑+氟维司群联合用药可延长乳腺癌患者生存, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f2f085501d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, objectTitle=比较氟维司群与阿那曲唑治疗晚期乳腺癌的多中心、随机、双盲、双模拟、安慰剂对照的Ⅲ期临床试验, objectType=article, longId=2150, objectId=f5cf2150c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5cf2150c7, replyNumber=0, likeNumber=78, createdTime=2010-09-21, rootId=0, userName=jiangfeng5068, userId=418d2846303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5cf2150c7, moduleTitle=比较氟维司群与阿那曲唑治疗晚期乳腺癌的多中心、随机、双盲、双模拟、安慰剂对照的Ⅲ期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f5cf2150c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

阿那曲唑

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#Giredestrant# #阿那曲唑# #乳腺癌#

Lancet Oncol | coopERA Breast Cancer研究：新辅助哌柏西利加giredestrant或阿那曲唑治疗雌激素受体阳性、HER2阴性的乳腺癌

2024-03-23发表于上海

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

JAMA Oncol：Vistusertib联合阿那曲唑治疗激素受体阳性子宫内膜癌

2022-05-17

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

Brit J Cancer：接受阿那曲唑治疗5年的绝经后妇女骨密度变化

2021-01-27

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

Lancet：阿那曲唑用于乳腺癌的预防

2019-12-18

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

CLIN CANCER RES：AKT抑制剂MK-2206联合阿那曲唑治疗Ⅱ/Ⅲ期PIK3CA突变ER阳性和HER-2阴性乳腺癌

2017-11-20

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

JNCI：化疗引发卵巢功能衰竭的乳腺癌患者使用阿那曲唑有无获益？

2017-11-05

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验

2017-06-25

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

Fertil Steril：雄激素缺乏生育力低下男性接受阿那曲唑结局有何改善？

2017-04-16

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

Fertil Steril.：雄激素缺乏生育力低下男性接受阿那曲唑结局有何改善？

2017-04-16

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

Lancet：对于雌激素受体阳性的晚期乳腺癌患者氟维司群疗效比阿那曲唑更好

2016-12-01

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

阿斯利康抗癌药Faslodex（氟维司群）治疗HR+晚期乳腺癌疗效显著优于Arimidex（阿那曲唑）

2016-05-30

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

Lancet：阿那曲唑 vs 他莫昔芬治疗对导管原位癌切除的绝经后女性生活质量的影响

2015-12-12

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

Lancet ：阿那曲唑治疗绝经后女性乳腺导管癌患者效果优于他莫昔芬

2015-12-12

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

JCO：阿那曲唑与腕管综合征发病率增高有关（基于国际乳腺癌干预研究II）

2015-11-26

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

Lancet Oncology：IBIS-II试验利塞膦酸钠可提高阿那曲唑骨质流失风险效益比

2014-11-13

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

Lancet：阿那曲唑，乳腺癌预防新选择

2013-12-27

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

NEJM：阿那曲唑+氟维司群联合用药可延长乳腺癌患者生存

2012-08-05

jiangfeng5068 (审核中...)

前往app查看评论内容

#阿那曲唑#

比较氟维司群与阿那曲唑治疗晚期乳腺癌的多中心、随机、双盲、双模拟、安慰剂对照的Ⅲ期临床试验

2010-09-21

科室
- - 订阅+
  - 更多科室
工具
服务